GNAS and neoplasm: This agreement indicates that KRAS mutations at codon 12 or GNAS mutations at codon 201 could play a key role as the driver of carcinogenesis, providing a selective advantage in tumor formation associated with these IPMNs (Parmigiani et al. 2009).